More older people (more than 65 years of age) around the world are getting Ulcerative Colitis (UC) or Crohn's Disease (CD). This is happening because people are living longer and because more people overall are developing UC or CD. Medicines that treat UC/CD, however, might make it easier for older adults to get infections. The main aim of this study is to learn if there is a difference in the number and type of infections in older people when treated with either ENTYVIO or other advance medicines (TNF-alpha inhibitors or ustekinumab) that reduce swelling and pain by blocking a chemical in the body (called TNF-alpha). The study will include people aged 65 years and older UC or CD who used either ENTYVIO with ustekinumab or a TNF-alpha inhibitor between 2016 and 2025. Data will be collected from existing Medicare databases.
Study Type
OBSERVATIONAL
Enrollment
23,900
This is an observational study, no intervention will be administered.
Percentage of Participants Hospitalized Due to Serious Infections
Serious infections will include infections of the respiratory tract, skin and soft tissue, genitourinary tract, gastrointestinal tract, central nervous system, and septicemia/sepsis. The intraabdominal infections, perianal infections, tuberculosis, and other opportunistic infections will not be considered under serious infection requiring hospitalization.
Time frame: Up to 4 months
Percentage of Participants with Non-serious Infections
Non-serious infections will include any primary diagnosis of infection that is not associated with hospitalization.
Time frame: Up to 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.